Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (SERA) delivers innovative diagnostic solutions for pregnancy complications through advanced biomarker technology. This news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones shaping maternal health diagnostics.
Access authoritative reporting on SERA's progress in precision medicine, including trial results for preterm birth prediction tests and collaborations with leading research institutions. Our curated news collection simplifies tracking of material events influencing the company's position in the $50B+ prenatal diagnostics market.
Key updates include FDA submissions for novel tests, peer-reviewed study publications, and commercial expansion initiatives. All content undergoes rigorous fact-checking to ensure compliance with financial disclosure standards while maintaining clinical accuracy.
Bookmark this page for real-time alerts on earnings announcements, intellectual property developments, and leadership changes. Stay informed about SERA's contributions to reducing neonatal complications through early intervention strategies validated by clinical evidence.
Sera Prognostics (Nasdaq: SERA) has been added to the Russell 2000 and 3000 indexes following the 2024 annual reconstitution finalized on June 28, 2024. Effective today, the company joins the list of the 4,000 largest US stocks ranked by market capitalization as of April 30, 2024. Membership in the Russell 3000 Index entails automatic inclusion in the Russell 1000 or Russell 2000 indexes, along with relevant growth and value style indexes. The Russell indexes are significant benchmarks, used by investment managers and institutional investors, with $10.5 trillion in assets benchmarked as of December 2023. This inclusion marks a notable milestone for Sera Prognostics, enhancing its visibility among key financial stakeholders.
Sera Prognostics, specializing in maternal and neonatal health, announced its inclusion in the preliminary list for the Russell 2000 and Russell 3000 indexes. The Russell indexes, managed by FTSE Russell, include the top 4,000 US stocks based on market capitalization as of April 30, 2024. This inclusion is for one year and will give Sera exposure to investment managers and institutional investors who use these indexes as benchmarks, involving about $10.5 trillion in assets. Sera's President and CEO, Zhenya Lindgardt, sees this as a significant milestone in the company’s mission to enhance pregnancy-related healthcare.
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), reported its first-quarter 2024 financial results, focusing on improving maternal and neonatal health through innovative pregnancy biomarker information. The company highlighted submitting PRIME study interim analysis results for publication, launching ambient whole blood collection kits to reduce costs and increase lab processing efficiency, and expanding into international markets. Despite revenue adjustments, operational expenses decreased, resulting in a narrower net loss compared to the same quarter in 2023.
Sera Prognostics Inc., a company focused on improving maternal and neonatal health, will report first quarter fiscal year 2024 financial results on May 8, 2024. The conference call and webcast will discuss operational highlights, financial results, and key topics at 5:00 p.m. Eastern Time. Details for the call are provided for both US domestic and international callers.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
